Language
English
Publication Date
1-13-2025
Journal
Molecular Cancer
DOI
10.1186/s12943-024-02211-8
PMID
39806486
PMCID
PMC11727718
PubMedCentral® Posted Date
1-13-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Lipid nanoparticles (LNPs) for mRNA delivery have advanced significantly, but LNP-mediated DNA delivery still faces clinical challenges. This study compared various LNP formulations for delivering DNA-encoded biologics, assessing their expression efficacy and the protective immunity generated by LNP-encapsulated DNA in different models. The LNP formulation used in Moderna's Spikevax mRNA vaccine (LNP-M) demonstrated a stable nanoparticle structure, high expression efficiency, and low toxicity. Notably, a DNA vaccine encoding the spike protein, delivered via LNP-M, induced stronger antigen-specific antibody and T cell immune responses compared to electroporation. Single-cell RNA sequencing (scRNA-seq) analysis revealed that the LNP-M/pSpike vaccine enhanced CD80 activation signaling in CD8
Keywords
Animals, Mice, Nanoparticles, Vaccines, DNA, Humans, Lipids, DNA, Female, CD8-Positive T-Lymphocytes, Biological Products, Liposomes, Lipid nanoparticles, DNA-encoded biologics, Vaccines, Monoclonal antibodies, Cancer immunotherapy
Published Open-Access
yes
Recommended Citation
Chai, Dafei; Wang, Junhao; Lim, Jing Ming; et al., "Lipid Nanoparticles Deliver DNA-Encoded Biologics and Induce Potent Protective Immunity" (2025). Faculty and Staff Publications. 4408.
https://digitalcommons.library.tmc.edu/baylor_docs/4408